X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
index medicus (45) 45
hematology (36) 36
middle aged (32) 32
oncology (31) 31
male (30) 30
aged (29) 29
female (27) 27
adult (25) 25
imatinib (22) 22
aged, 80 and over (21) 21
cancer (19) 19
leukemia (18) 18
analysis (15) 15
imatinib mesylate (15) 15
chronic myeloid leukemia (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - genetics (14) 14
mutation (14) 14
aneuploidy (13) 13
diagnosis (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (13) 13
adolescent (12) 12
chromosome aberrations (12) 12
chronic myeloid-leukemia (12) 12
animals (11) 11
antineoplastic agents - therapeutic use (10) 10
genetic instability (10) 10
hemic and lymphatic diseases (10) 10
mutations (10) 10
pyrimidines - therapeutic use (10) 10
cells (9) 9
cytogenetics (9) 9
genetics & heredity (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - pathology (9) 9
multidisciplinary sciences (9) 9
myeloid leukemia (9) 9
patients (9) 9
piperazines - therapeutic use (9) 9
benzamides (8) 8
chronic myelogenous leukemia (8) 8
fusion proteins, bcr-abl - genetics (8) 8
karyotyping (8) 8
medicine & public health (8) 8
tyrosine kinase inhibitors (8) 8
young adult (8) 8
antimitotic agents (7) 7
antineoplastic agents (7) 7
care and treatment (7) 7
cell biology (7) 7
cell line, tumor (7) 7
chromosomal instability (7) 7
classification (7) 7
clonal evolution (7) 7
gene expression (7) 7
genetic aspects (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - mortality (7) 7
neoplasms - genetics (7) 7
remission induction (7) 7
research article (7) 7
survival (7) 7
therapy (7) 7
treatment outcome (7) 7
tumors (7) 7
centrosomes (6) 6
dasatinib (6) 6
disease (6) 6
evolution (6) 6
follow-up (6) 6
hematology, oncology and palliative medicine (6) 6
medicine (6) 6
myelodysplastic syndromes (6) 6
myeloproliferative disorders (6) 6
platelet-derived growth factor (6) 6
polymerase chain reaction (6) 6
prognosis (6) 6
protein kinase inhibitors - therapeutic use (6) 6
receptor, platelet-derived growth factor beta - genetics (6) 6
risk factors (6) 6
science (6) 6
time factors (6) 6
abridged index medicus (5) 5
article (5) 5
biomarkers, tumor - genetics (5) 5
chronic myelomonocytic leukemia (5) 5
cricetinae (5) 5
cricetulus (5) 5
disease progression (5) 5
expression (5) 5
genes (5) 5
kaplan-meier estimate (5) 5
kinases (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (5) 5
mastocytosis, systemic - genetics (5) 5
molecular sequence data (5) 5
neoplasms (5) 5
oncogene proteins, fusion - genetics (5) 5
proto-oncogene proteins c-kit - genetics (5) 5
pyrimidines - adverse effects (5) 5
remission (5) 5
research (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 747 - 757
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a... 
SURVIVAL | MAJOR MOLECULAR RESPONSE | TREATMENT-FREE REMISSION | ONCOLOGY | IMATINIB DISCONTINUATION | DISEASE | FOLLOW-UP | DASATINIB | WITHDRAWAL SYNDROME | NILOTINIB | PHASE-2 TRIAL | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Clinical Decision-Making | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Risk Assessment | Europe | Risk Factors | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Progression-Free Survival | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Antimitotic agents | Tyrosine | Antineoplastic agents | Analysis | Life Sciences | Hematology | Human health and pathology | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2018, Volume 13, Issue 1, p. e0191734
ESPL1/separase, a cysteine endopeptidase, is a key player in centrosome duplication and mitotic sister chromatid separation. Aberrant expression and/or altered... 
OVEREXPRESSION | CENTRIOLES | AMPLIFICATION | MULTIDISCIPLINARY SCIENCES | COHESIN PROTEASE SEPARASE | RISK MYELODYSPLASTIC SYNDROMES | HUMAN CANCERS | MUTATIONS | CHRONIC MYELOID-LEUKEMIA | CHROMOSOMAL INSTABILITY | CELL-DEATH
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2014, Volume 93, Issue 1, pp. 81 - 88
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0133769
Journal Article